The incorporation of MF59 as a combination adjuvant with the Polymyxin B formulation significantly increased CD80 expression in comparison to the Polymyxin-adjuvanted gonorrhea vaccine, whereas Alum did not. The gene discussed is CD80; the disease is gonorrhea.